Multiplex Enzyme Complementation Assay for Rapid Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing high-throughput drug screening methods are time-consuming, expensive, and tedious, and require special training, making them unsuitable for rapid screening of large numbers of chemical compounds to identify new drug candidates.
Innovation Solution
A modified enzyme complementation assay using a nuclease acceptor and donor that form a functional nuclease complex capable of cleaving a labeled nucleic acid substrate, where the presence of a test compound that interacts with the target polypeptide prevents denaturation, allowing for rapid detection of potential drug candidates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional high-throughput drug screening methods are used, then drug candidates can be identified, but the process is time-consuming and requires special training
Solution Approach 1:
The patent replaces complex mechanical/chemical screening systems with a simplified enzyme complementation assay based on nuclease activity. The assay uses a fusion protein containing a target polypeptide and a nuclease acceptor domain, which when bound by a test compound, activates nuclease donor to cleave a substrate and produce a fluorescent signal. This substitution of complex screening mechanics with a simple enzymatic readout enables rapid automated screening without requiring specialized training.
Solution Approach 2:
The patent changes the detection parameter from complex biochemical measurements to simple fluorescent signal intensity. By using a fluorogenic substrate that emits fluorescence upon cleavage, the assay transforms the binding event into a quantifiable optical parameter that can be rapidly measured by standard plate readers, dramatically increasing screening throughput and reducing time requirements.
2Measurement precision
If traditional screening methods are used, then drug interactions can be detected, but the process is expensive and tedious
Solution Approach 1:
The patent segments the detection system into modular components: a fusion protein with target polypeptide and nuclease acceptor domain, a separate nuclease donor, and a fluorogenic substrate. This segmentation allows each component to be independently optimized and simplifies the overall assay protocol, making it easier to manufacture and implement while maintaining high detection precision through the specific enzymatic interaction.
Solution Approach 2:
The patent introduces an intermediary enzymatic reaction system where the nuclease acceptor-donor complex acts as a mediator between the test compound binding event and the fluorescent signal. This intermediary mechanism provides a clear, amplifiable readout that enhances measurement precision while simplifying the direct detection process, as the enzymatic amplification makes the signal easily measurable without complex instrumentation.
3Productivity
If rapid screening is implemented, then screening time is reduced, but automation and multiplexing capability must be enhanced
Solution Approach 1:
The patent designs a universal assay platform that can screen multiple targets and compounds using the same basic protocol and reagents. The fusion protein system can be adapted to different target polypeptides, and the assay format works in standard microplate formats (96-well, 384-well), enabling multiplexing and automated high-throughput screening without requiring method development for each specific target, thus reducing automation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay is rapid, inexpensive, and amenable to automation, enabling high-throughput screening of hundreds to thousands of compounds in a short time, providing quantitative measures of drug binding and identifying effective drug candidates.
Implementation Method 1
a modified type of enzyme complementation assay that requires the assembly of two components, a nuclease acceptor and a nuclease donor, that can assemble into a functional nuclease complex capable of cleaving a labeled nucleic acid substrate
Implementation Method 2
The assay is conducted, in certain embodiments, in the presence of a test compound and a denaturant (e.g., heat) that denatures the fusion protein and prevents assembly of an active nuclease complex
Implementation Method 3
the nucleic acid substrate comprises a pair of FRET labels. In some embodiments, the amount of the cleavage product comprises detecting an amount of a fluorescence signal emitted from the cleavage product
Data Source
AI summary
Provided herein are methods amenable to high-throughput multiplexing, in part, using a modified enzyme complementation assay, that can be used to screen a library of test compounds and to identify compounds that inhibit denaturation of a target polypeptide of interest.